PerQseal® Clinical Study (PATCH)

A Multicentre, Single-Arm, Pivotal Study to Evaluate the Safety and Efficacy of the Vivasure PerQseal® Closure Device System When Used to Achieve Haemostasis of Common Femoral Arteriotomies Created by 12 to 22 F Sheaths in Patients Undergoing Percutaneous Catheter-Based Interventional Procedures

The objective is to evaluate the safety and effectiveness of the PerQseal vascular closure device system when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing percutaneous catheter-based interventional procedures.

Study Overview

• Status: Active, not recruiting
• Conditions: Percutaneous Large Hole Vascular Closure
• Intervention / Treatment: Device: PerQseal® Closure Device System

Detailed Description

The objective of this pivotal study is to evaluate the safety and effectiveness of the PerQseal vascular closure device system when used to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing percutaneous catheter-based interventional procedures, with sufficient rigor to provide robust scientific evidence for the demonstration of clinical safety and efficacy of the PerQseal closure system to support a pre-market approval submission.

• Study Type: Interventional
• Enrollment (Actual): 149
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 10713
    • St. Gertrauden Krankenhaus (SGK)
  • North Rhine-Westphalia
    • Muenster, North Rhine-Westphalia, Germany
      • St Franziskus Hospital
  • Saxony
    • Leipzig, Saxony, Germany, 04103
      • Leipzig University Hospital
• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85258
      • HonorHealth
  • California
    • La Jolla, California, United States, 92037
      • Scripps
  • Maine
    • Bangor, Maine, United States, 04401
      • Northern Light Eastern Maine Medical Center
  • New Jersey
    • Camden, New Jersey, United States, 08103
      • Cooper University Hospital
    • Paramus, New Jersey, United States, 07652
      • The Valley Hospital
  • New York
    • Bronx, New York, United States, 10461
      • Montefiore Medical Center (multiple centers)
    • Buffalo, New York, United States, 14203
      • University of Buffalo
    • New York, New York, United States, 10032
      • Columbia University Medical Center/ NewYork Presbyterian Hospital
    • Rochester, New York, United States, 14623
      • University of Rochester Medical Center
    • Stony Brook, New York, United States, 11794
      • Stony Brook University Hospital
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • The Cleveland Clinic
  • Pennsylvania
    • Mechanicsburg, Pennsylvania, United States, 17050
      • UPMC Pinnacle Health
    • Philadelphia, Pennsylvania, United States, 19104
      • UPenn - Perelman Center for Advanced Medicine,
    • Wynnewood, Pennsylvania, United States, 19096
      • Lankenau Institute for Medical Research
  • Texas
    • Houston, Texas, United States, 77030
      • The Texas Heart Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥ 19 years,
2. Clinically indicated for a percutaneous arterial interventional catheter-based procedure, e.g., transcatheter aortic valve replacement/implantation (TAVR/TAVI) or endovascular abdominal aortic aneurysm repair (EVAR), or thoracic endovascular aortic aneurysm repair (TEVAR), or use of a circulatory assist device or extracorporeal oxygenation using a common femoral arteriotomy created by a 12 to 22 F sheath (arteriotomy up to 26 F),
3. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements,
4. Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.

Baseline Exclusion Criteria:

1. Evidence of current systemic bacterial or cutaneous infection, including groin infection,
2. Known bleeding diathesis, definite or potential coagulopathy, platelet count < 100,000/µl or subjects on long term anticoagulants with an INR > 2 within 12 hours prior to index procedure,
3. Significant anaemia (haemoglobin < 9 g/dL or haematocrit < 27%), within 24 hours prior to index procedure,
4. Known type II heparin-induced thrombocytopenia,
5. Documented left ventricular ejection fraction < 20%,
6. Ipsilateral or contralateral lower extremity amputation.
7. Claudication (Rutherford category 3 or greater), documented untreated iliac or common femoral artery diameter stenosis > 50% or previous bypass surgery/stent placement in the common femoral artery of target leg,
8. Known existing nerve damage in the target leg,
9. Renal insufficiency (Glomerular Filtration Rate ≤ 30 ml/min or baseline serum creatinine > 2.5 mg/dL) or on renal replacement therapy,
10. Known allergy to any of the materials used in the PerQseal device (refer to Instructions for Use),
11. Subject unsuitable for surgical repair of the target leg access site,
12. Subject has undergone a percutaneous procedure greater than 8 F sheath in the target leg, within the 90-days prior to index procedure,
13. Subject has undergone a percutaneous procedure of 8 F sheath or less using an absorbable intravascular closure device for haemostasis, in the target leg, within the 90-days prior to index procedure,
14. Subject has undergone a percutaneous procedure of 8 F sheath or less using a suture mediated closure device or manual/mechanical pressure for haemostasis in the target leg, within the 30-days prior to index procedure,
15. Evidence of marked tortuosity of the femoral or external iliac arteries in the target leg, based on pre-primary procedure CT angiography,
16. Evidence of arterial diameter stenosis > 30% within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography,
17. Evidence of anterior wall calcification of the target common femoral artery (other than small, diffuse deposits which in the opinion of the investigator will not impede the vascular closure procedure) within 15 mm proximal or distal to arteriotomy site based on pre-primary procedure CT angiography,
18. Target femoral artery diameter is less than 6 mm or 7 mm, depending on whether S (small) or L (large) PerQseal Introducer will be used for arteriotomy closure, respectively, based on pre-primary procedure CT angiography,
19. Further planned endovascular/catheter-based procedure in the target leg in the 30-days following the index procedure.
20. Subject is enrolled in another investigational medical device or drug study,
21. Subject has been previously enrolled in this clinical study.

22. Current COVID-19 infection (with or without symptoms), recent positive test for COVID-19 within two weeks, or recent exposure to a person with COVID-19 infection within two weeks.

    Procedural Exclusion Criteria:

    If any Procedural Exclusion Criteria listed below are met, then closure with PerQseal device is not permitted.

23. Initial common femoral arterial access achieved with manual palpation or blind arterial stick access, without use of an image guided approach (ultrasound or angiography).
24. Difficult dilation during initial target femoral artery access (e.g., that damages or kinks dilators) while step-dilating up to the large-bore device,
25. During arterial puncture, the target femoral artery suspected to have experienced a posterior arterial wall needle puncture or underwent > one needle puncture during the primary procedure (with a needle larger than a Micropuncture needle (> 21 gauge or > 0.819 mm diameter) )
26. Subject has a tissue tract (i.e., estimated distance from skin entry point to arterial anterior surface at arteriotomy) expected to be greater than 8 cm.,
27. Significant blood loss requiring transfusion of blood products during primary procedure or within 30-days prior to index procedure,
28. Activated clotting time (ACT) > 250 seconds immediately prior to sheath removal or if ACT measurements are expected to be > 250 seconds for more than 24 hours after index procedure,
29. Target puncture site is in a vascular graft,
30. Target arteriotomy greater than 26 F,
31. Target arteriotomy in the profunda femoris or superficial femoral artery or is in common femoral artery, but within 15 mm proximal of the bifurcation of the superficial femoral/ profunda femoris artery,
32. Target arteriotomy located at the level or above the inferior epigastric artery and/or beneath or above the inguinal ligament based on bony/arterial landmarks (above femoral head on A-P projection),
33. Subjects with an acute haematoma > 4 cm diameter, arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the target access site identified intra-procedurally,
34. Evidence of bleeding around the primary procedure sheath (VARC type1/BARC type 2 or higher),
35. Intra-procedural angiographic evidence of arterial laceration, dissection or stenosis within the femoral artery that would preclude use of the PerQseal device,
36. Uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg) at the time of planned vascular closure,
37. Systolic blood pressure < 90 mmHg at the time of planned vascular closure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Subjects implanted with PerQseal Vascular Closure Device; Subjects implanted with bioabsorbable implant to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.	Device: PerQseal® Closure Device System; Bioabsorbable implant delivered percutaneously to achieve haemostasis of common femoral arteriotomies created by 12 to 22 F sheaths (up to 26 F arteriotomy) in patients undergoing percutaneous catheter-based interventional procedures.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Safety Endpoint - Major Access Site Complications	Rate of major access site complications attributable to the PerQseal device	through 30 days
Primary Effectiveness Endpoint - Time to Hemostasis	Elapsed time in minutes from PerQseal (Introducer-sheath and Delivery Device) removal to first observed cessation of common femoral artery (CFA) bleeding, excluding cutaneous or subcutaneous oozing, and in the absence of a developing haematoma.	20 Minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary Safety Endpoint - Minor Access Site Complications	Incidence of minor access site complications attributable to the PerQseal device	through 30 Days
Secondary Effectiveness Endpoint - PerQseal Technical Success Rate	Defined as the number of PerQseal devices that are deployed and achieve haemostasis (i.e., cessation of arterial bleeding excluding cutaneous or subcutaneous oozing) without need for more than 10 minutes of firm, adjunctive manual compression or alternative treatment (other than adjunctive endovascular ballooning) at target access site, divided by the total number of PerQseal devices where deployment was attempted. This is a per device endpoint.	10 Minutes
Secondary Effectiveness Endpoint - PerQseal Treatment Success Rate	Defined as the number of subjects who meet PerQseal Technical Success without experiencing a device related Major Access Site Complication through 30-days, divided by the total number of subjects where PerQseal device deployment was attempted.	through 30 days
Secondary Effectiveness Endpoint - Time to Device Deployment	Defined as the time from insertion of the PerQseal delivery device into the PerQseal Introducer sheath to complete removal of the PerQseal (delivery device and introducer-sheath) from the subject following PerQseal deployment.	20 Minutes
Secondary Effectiveness Endpoint - Time to Ambulation	Defined as the elapsed time from PerQseal removal until the subject can walk 20 feet/ 6 meters without arterial re-bleeding at the target access site. This endpoint will be evaluated only for subjects who are ambulatory (e.g., not confined to wheelchair or bed) at time of enrolment.	through 24 hours
Secondary Effectiveness Endpoint - Total Closure Time	Defined as time to Haemostasis plus Time to Device Deployment.	40 Minutes

Collaborators and Investigators

• Sponsor: Vivasure Medical Limited
• Investigators: Principal Investigator: William Gray, Dr., Lankenau Heart Institute; Principal Investigator: Sean Lyden, Dr., The Cleveland Clinic

Study record dates

Study Major Dates

• Study Start (Actual): March 30, 2023
• Primary Completion (Actual): December 16, 2024
• Study Completion (Estimated): June 1, 2025

Study Registration Dates

• First Submitted: December 7, 2022
• First Submitted That Met QC Criteria: December 7, 2022
• First Posted (Actual): December 16, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: January 23, 2025
• Last Verified: January 1, 2025

More Information

Terms related to this study

• Keywords: Vascular Closure Device; Vascular Closure; Large hole percutaneous closure; Large bore percutaneous closure
• Other Study ID Numbers: P696-00

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No